ライフサイエンスコーパス: mycophenolate

1 and Ret(9/-) (with aganglionosis induced by mycophenolate).

2 sease prophylaxis (calcineurin inhibitor and mycophenolate).

3 methylprednisolone infusions, prednisone and mycophenolate.

4 with or without a calcineurin inhibitor and mycophenolate.

5 e obtained using mTOR inhibitors compared to mycophenolate.

6 mtuzumab/tacrolimus or daclizumab/tacrolimus/mycophenolate.

7 osuppression (IS) consisted of sirolimus and mycophenolate.

8 nts were treated with prednisone 1 mg/kg and mycophenolate 2 g daily.

9 Immunosuppression was escalated to mycophenolate 3 g daily, with addition of a second agent

10 used immunosuppressive agents tacrolimus and mycophenolate, albeit with appropriate dose adjustment.

11 Here we found that mycophenolate, an inhibitor of de novo guanine nucleotid

12 ression of RAIDs (i.e. rituximab, belimumab, mycophenolate and azathioprine).

13 The oral immunosuppressive drugs used were mycophenolate and cyclophosphamide.

14 unosuppression, with concomitant tacrolimus, mycophenolate and standard dose daclizumab (SB group) or

15 uction, rapid steroid taper, and maintenance mycophenolate and tacrolimus, to 2 arms using maintenanc

16 pients received calcineurin inhibitor (CNI), mycophenolate, and posttransplant cyclophosphamide for g

17 rst 3 years postoperatively were tacrolimus, mycophenolate, and steroids, and later, tacrolimus, siro

18 tation in recipients receiving prednisolone, mycophenolate, and tacrolimus.

19 Initial treatment with rituximab, mycophenolate, and, to a lesser degree, azathioprine sig

20 spectrum disorder treated with azathioprine, mycophenolate, and/or rituximab at the Mayo Clinic and t

21 verse effects associated with tacrolimus and mycophenolate are complex, and recipient risk is not det

22 The immunosuppressants tacrolimus and mycophenolate are important components to the success of

23 methotrexate, azathioprine, leflunomide, and mycophenolate, are often used as alternatives to steroid

24 nisolone with cyclosporine, azathioprine, or mycophenolate as steroid-sparing agents.

25 systemic sclerosis, and 48.4% were receiving mycophenolate at baseline.

26 review, the totality of evidence supporting mycophenolate CCD is examined: pharmacological character

27 Fixed dosing of mycophenolate consistently leads to underexposure associ

28 nistered standardized basiliximab-tacrolimus-mycophenolate-corticosteroid immunosuppressive therapy,

29 suggest a need to escalate therapy to higher mycophenolate doses, and in one fifth of cases to add a

30 (early azathioprine era: 1990-2000 vs modern mycophenolate era: 2000-2011).

31 the methotrexate group vs 14 (63.6%) in the mycophenolate group (difference, -30.3% [95% CI, -51.6%

32 the methotrexate group vs 42 (55.3%) in the mycophenolate group (difference, 19.1% [95% CI, 3.6% to

33 the methotrexate group vs 56 (57.1%) in the mycophenolate group (difference, 9.5% [95% CI, -5.3% to

34 hotrexate group and 8 patients (7.4%) in the mycophenolate group.

35 in 4627 children who received tacrolimus and mycophenolate immunosuppression and did not have multior

36 in consecutive recipients taking tacrolimus/mycophenolate immunosuppression at a single center.

37 , donor hematopoietic stem cells, tacrolimus/mycophenolate immunosuppression converted to sirolimus,

38 closporine was combined with azathioprine or mycophenolate in cases unresponsive to only 1 of these d

39 combining atorvastatin with cyclosporine or mycophenolate in place of rapamycin was ineffective.

40 different mouse models of HSCR, addition of mycophenolate increased the penetrance and severity of H

41 S precursor proliferation most likely causes mycophenolate-induced migration defects and aganglionosi

42 To the best of our knowledge, mycophenolate is the first medicine identified that caus

43 The immunosuppressive agent mycophenolate is used extensively in kidney transplantat

44 emtuzumab (C1H) induction and tacrolimus and mycophenolate maintenance with switch to sirolimus and w

45 ansplantation (KT) includes a combination of mycophenolates (MMF/MPA) with a calcineurin inhibitor (C

46 (1.61 [1.11-2.34], P = 0.01), treatment with mycophenolate mofetil (0.68 [0.47-0.97], P = 0.03).

47 n (1.61 [1.11-2.34], p=0.01), treatment with mycophenolate mofetil (0.68 [0.47-0.97], p= 0.03).

48 ly for 2 days) and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28)

49 , total body irradiation, cyclosporine A and mycophenolate mofetil (12 doses), and antilymphocyte ser

50 Post grafting immunosuppression consisted of mycophenolate mofetil (28 days) and cyclosporine (35 day

51 vents was higher with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).

52 or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%).

53 nation therapy with IFN-beta-1a (Avonex) and mycophenolate mofetil (Cellcept) modulated the hyperphos

54 or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose c

55 Mycophenolate mofetil (MMF) and combination therapies in

56 Prophylactic drugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), ar

57 acrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart tra

58 ceiving tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and those maintained on a re

59 Nowadays, tacrolimus (Tac) and mycophenolate mofetil (MMF) are considered more efficien

60 atical model using T- and B-cell markers and mycophenolate mofetil (MMF) dosage.

61 olimus in addition to cyclosporine (CSP) and mycophenolate mofetil (MMF) for graft-versus-host diseas

62 d with tacrolimus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individuall

63 calcineurin inhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine pract

64 Rapamycin and mycophenolate mofetil (MMF) have been used for maintenan

65 well as to characterize dose adjustments of mycophenolate mofetil (MMF) in this setting.

66 ebo-controlled study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(

67 nzyme activity and adverse effects caused by mycophenolate mofetil (MMF) inhibition may be geneticall

68 Mycophenolate mofetil (MMF) is an immunosuppressive agen

69 The use of mycophenolate mofetil (MMF) is associated with less acut

70 The prodrug ester mycophenolate mofetil (MMF) is frequently used in solid-

71 ssigned 1:1 on day 28 posttransplantation to mycophenolate mofetil (MMF) or Everolimus combined with

72 -blinded trial, was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was sup

73 Mycophenolate mofetil (MMF) side effects often prompt do

74 st basiliximab induction with tacrolimus and mycophenolate mofetil (MMF) therapy in renal transplanta

75 Rodnan skin score (MRSS) improvement during mycophenolate mofetil (MMF) treatment.

76 udy was to assess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blo

77 We examined the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiograp

78 rd maintenance dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids.

79 icularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids.

80 All patients were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and p

81 rolled trial comparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticoster

82 itor (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF).

83 ines were treated with the immunosuppressant mycophenolate mofetil (MMF).

84 ng maintenance with both corticosteroids and mycophenolate mofetil (MMF).

85 eated with the combination of tacrolimus and mycophenolate mofetil (MMF).

86 drug and a calcineurin inhibitor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacroli

87 eived tacrolimus (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 60 mg/kg per day), and anti-

88 ip), tacrolimus (FK506; 0.1-0.5-1 mg/kg ip), mycophenolate mofetil (MMF; 60-120-300 mg/kg oral) or ve

89 ficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic a

90 uding sirolimus (n = 5), bortezomib (n = 3), mycophenolate mofetil (n = 2), splenectomy (n = 2), and

91 42 patients were randomly assigned to either mycophenolate mofetil (n=69) or cyclophosphamide (n=73).

92 tment success with methotrexate and 47% with mycophenolate mofetil (P = 0.09).

93 ), and higher mean tacrolimus (P=0.0009) and mycophenolate mofetil (P=0.01) blood levels.

94 lant or to continue standard tacrolimus with mycophenolate mofetil (sTAC/MMF) and steroids.

95 mmy, centre-blocked design to receive either mycophenolate mofetil (target dose 1500 mg twice daily)

96 drawal at 6-month posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTA

97 on days 3 and 4 after transplantation, oral mycophenolate mofetil 15 mg/kg per dose (maximum 1 g) ev

98 itor-withdrawn, sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day.

99 idine, azaribine, pyrazofurin [PF], AVN-944, mycophenolate mofetil [MMF], and mycophenolic acid [MPA]

100 126 patients (mycophenolate mofetil [n=63] and cyclophosphamide [n=63]

101 olimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/

102 with patients treated with cyclosporine and mycophenolate mofetil alone.

103 d prolonged-release tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intraoperative cort

104 16 (11%) patients died (five [7%] mycophenolate mofetil and 11 [15%] cyclophosphamide), wi

105 ly assigned to maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine).

106 aCD20 antibody, followed by maintenance with mycophenolate mofetil and an intensively dosed alphaCD40

107 e that conventional immunomodulators such as mycophenolate mofetil and biologics such as rituximab ar

108 QD 0.3 mg/kg per day (Arm 3; n=304) all with mycophenolate mofetil and corticosteroids (tapered) over

109 regimens or placebo, both on a background of mycophenolate mofetil and corticosteroids.

110 2) standard-exposure cyclosporine, both with mycophenolate mofetil and corticosteroids; 95/115 random

111 the % FVC improved significantly in both the mycophenolate mofetil and cyclophosphamide groups.

112 her abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids.

113 All patients received cyclosporine and mycophenolate mofetil and gradually tapered prednisone.

114 nt and graft survivals after introduction of mycophenolate mofetil and induction with basiliximab.

115 ts given CBMPs were successfully weaned from mycophenolate mofetil and maintained on tacrolimus monot

116 e active immunosuppressive substance in both mycophenolate mofetil and mycophenolate sodium, and it i

117 py with rabbit ATG, mycophenolate sodium, or mycophenolate mofetil and rapid withdrawal of steroids.

118 d with 30% to 50% reduction in doses of both mycophenolate mofetil and Tac without antiviral therapy.

119 ipeptidylpeptidase-deficient F344 rats using mycophenolate mofetil and tacrolimus for partial lymphoc

120 py with a T cell-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the mo

121 Mycophenolate mofetil and TNF-alpha antagonists can be u

122 ly oral methotrexate or 1 g twice daily oral mycophenolate mofetil and were monitored monthly for 6 m

123 inhibitor (CNI) dose or conversion to either mycophenolate mofetil and/or rapamycin resulted in varia

124 Methotrexate and mycophenolate mofetil are commonly used immunomodulatory

125 Both MPA and mycophenolate mofetil are highly specific inhibitors of

126 Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gu

127 Mycophenolate mofetil at intensified and individually ad

128 h enteric-coated mycophenolate sodium versus mycophenolate mofetil at month 6 among African Americans

129 lung disease, and the present preference for mycophenolate mofetil because of its better tolerability

130 ther reduced calcineurin inhibitor (CNI) and mycophenolate mofetil by 30% to 50% (n=23), or we switch

131 dults with noninfectious uveitis, the use of mycophenolate mofetil compared with methotrexate as firs

132 SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mofetil de novo, and (d) conversion from C

133 Mycophenolate mofetil did not provide mycophenolic acid

134 Mycophenolate mofetil dose reduction was independently a

135 In the triple-drug group, mycophenolate mofetil doses were the same as in the stan

136 dose equal to or more than 2000 mg per day (mycophenolate mofetil equivalents) was significantly hig

137 Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between gro

138 derma-related interstitial lung disease with mycophenolate mofetil for 2 years or cyclophosphamide fo

139 l effectiveness of both cyclophosphamide and mycophenolate mofetil for progressive scleroderma-relate

140 ed from baseline to 24 months by 2.19 in the mycophenolate mofetil group (95% CI 0.53-3.84) and 2.88

141 thioprine group and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), and the rate of

142 ilure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the

143 ptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0

144 same conditioning regimen with sirolimus and mycophenolate mofetil immune suppression.

145 llowed by a short course of cyclosporine and mycophenolate mofetil immunosuppression.

146 olonged-release tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive regimen is effic

147 solimumab nonimprovers were downregulated in mycophenolate mofetil improvers, suggesting that immunom

148 rmine whether rituximab with azathioprine or mycophenolate mofetil improves the high-resolution compu

149 We compared Everolimus versus mycophenolate mofetil in an investigator-initiated singl

150 hymocyte globulin induction, tacrolimus, and mycophenolate mofetil is associated with excellent patie

151 ith interstitial lung disease (ILD), whereas mycophenolate mofetil is effective in both polymyositis

152 Prednisolone, tacrolimus, and mycophenolate mofetil modified fecal microbiota at the f

153 The effect of sirolimus or mycophenolate mofetil on NK cells was minimal.

154 es immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with gluco

155 nts received systemic immunosuppression with mycophenolate mofetil or cyclosporine A.

156 had worsened gastrointestinal symptoms with mycophenolate mofetil or EC-MPS in combination with Tac

157 Whether treatments such as mycophenolate mofetil or statins have a role in preventi

158 antithymocyte globulin induction followed by mycophenolate mofetil plus calcineurin inhibitors (n=28,

159 uded maintenance therapy with belatacept and mycophenolate mofetil plus induction with basiliximab an

160 loped stable graft function for >=2 years on mycophenolate mofetil plus prednisone.

161 adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with

162 ritis confirmed with biopsy and treated with mycophenolate mofetil presented with a 2-day history of

163 uccess in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients wit

164 g sirolimus to the standard cyclosporine and mycophenolate mofetil prophylaxis therapy for preventing

165 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a

166 he addition of sirolimus to cyclosporine and mycophenolate mofetil resulted in a lower incidence of a

167 Adding sirolimus to cyclosporine and mycophenolate mofetil resulted in a significantly lower

168 followed by tacrolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg thre

169 mab induction was substituted with CBMPs and mycophenolate mofetil tapering was allowed.

170 Fewer patients on mycophenolate mofetil than on cyclophosphamide premature

171 Combined prednisone and mycophenolate mofetil therapy is a potentially effective

172 Switching from mycophenolate mofetil to leflunomide successfully cleare

173 molluscum contagiosum who were switched from mycophenolate mofetil to leflunomide.

174 It compared the addition of mycophenolate mofetil to steroids vs steroids/placebo to

175 for 2 weeks after each infusion); rapamycin+mycophenolate mofetil treatment as maintenance therapy.

176 Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) ce

177 either 25 mg oral methotrexate weekly or 1 g mycophenolate mofetil twice daily, with a corticosteroid

178 IS consisted of ATG, anti-CD154mAb, and mycophenolate mofetil until age 8 to 12 months.

179 while low DNAemia rates were associated with mycophenolate mofetil use (p < 0.0001) and EBV viral cap

180 d response system, stratified by concomitant mycophenolate mofetil use and presence or absence of int

181 acrolimus elimination at 3 months versus SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mo

182 Mycophenolate mofetil was associated with PCP risk only

183 Although mycophenolate mofetil was better tolerated and associate

184 standard GVHD prophylaxis group, 15 mg/kg of mycophenolate mofetil was given orally three times daily

185 Mycophenolate mofetil was initiated postoperatively with

186 Use of mycophenolate mofetil was inversely associated with vacc

187 , the addition of a calcineurin inhibitor or mycophenolate mofetil was predictive for maintaining a D

188 Mycophenolate mofetil was superior to azathioprine in ma

189 Mycophenolate mofetil was superior to azathioprine with

190 Mycophenolate mofetil was the treatment in 10 patients,

191 Tacrolimus and mycophenolate mofetil were required as well as either ra

192 ab 1 month before transplant; tacrolimus and mycophenolate mofetil were started 1 week before surgery

193 enance immunosuppression with tacrolimus and mycophenolate mofetil with/without steroids.

194 mmunosuppression consisted of tacrolimus and mycophenolate mofetil without induction or depletional t

195 We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated,

196 I 1.09-2.93, compared with use of tacrolimus/mycophenolate mofetil) and following a diagnosis of cuta

197 A total of 67 patients (35 methotrexate, 32 mycophenolate mofetil) contributed to the primary outcom

198 d GVHD prophylaxis regimen (cyclosporine and mycophenolate mofetil) or the triple-drug combination re

199 e 5'-monophosphate dehydrogenase inhibitors (mycophenolate mofetil) to the immunosuppressive armament

200 ive oral methotrexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followe

201 Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclo

202 ethotrexate, 25 mg weekly (n = 107), or oral mycophenolate mofetil, 3 g daily (n = 109).

203 preva Lupus Management Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment

204 es (95% CI: 0.6, 9.8; P = .20) the odds with mycophenolate mofetil, a difference that was not statist

205 nolic acid (MPA) is the active metabolite of mycophenolate mofetil, a drug that is widely used for im

206 nolic acid (MPA) is the active metabolite of mycophenolate mofetil, an effective immunosuppressive dr

207 plored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone,

208 on and triple maintenance therapy (steroids, mycophenolate mofetil, and calcineurin inhibitor).

209 ession consisted of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of pat

210 or induction in combination with tacrolimus, mycophenolate mofetil, and corticosteroids.

211 All subjects received basiliximab induction, mycophenolate mofetil, and corticosteroids.

212 d tritherapy associating standard-dose CNIs, mycophenolate mofetil, and corticosteroids.

213 ter transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids.

214 ldren with SLE received cyclophosphamide and mycophenolate mofetil, and more children with JIA receiv

215 (90% CI 0.54-0.94; p=0.044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

216 thotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

217 (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

218 and 67 (73%) grade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

219 Tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

220 ere haematological (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

221 ppressive regime consisting of cyclosporine, mycophenolate mofetil, and prednisolone were well tolera

222 ept or tacrolimus combined with basiliximab, mycophenolate mofetil, and prednisolone.

223 te globulin, methylprednisolone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

224 d rabbit antithymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone.

225 se results, the combination of cyclosporine, mycophenolate mofetil, and sirolimus has become the new

226 iple-drug combination regimen (cyclosporine, mycophenolate mofetil, and sirolimus).

227 GVHD prophylaxis comprised cyclosporine, mycophenolate mofetil, and sirolimus.

228 ntithymocyte globulin induction, tacrolimus, mycophenolate mofetil, and steroid withdrawal by day 5 a

229 ion therapy, in combination with tacrolimus, mycophenolate mofetil, and steroids.

230 ndardized immunosuppression with tacrolimus, mycophenolate mofetil, and steroids.

231 tithymocyte globulin, calcineurin inhibitor, mycophenolate mofetil, and steroids.

232 ttransplantation high-dose cyclophosphamide, mycophenolate mofetil, and tacrolimus or sirolimus.

233 ing, T-cell-replete allografting, then PTCy, mycophenolate mofetil, and tacrolimus.

234 e group given basiliximab, tapered steroids, mycophenolate mofetil, and tacrolimus.

235 eks, or tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids

236 and immunosuppression regimes (azathioprine, mycophenolate mofetil, calcineurin inhibitors, mammalian

237 ee immunosuppressive regimen, when used with mycophenolate mofetil, corticosteroids, and anti-interle

238 her a CNI-free regimen, including sirolimus, mycophenolate mofetil, corticosteroids, and anti-interle

239 corticosteroids, cyclophosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchicine, hydro

240 unosuppressive protocol included tacrolimus, mycophenolate mofetil, prednisone, and antithymocyte glo

241 pressive treatment that included tacrolimus, mycophenolate mofetil, prednisone, and, for induction, a

242 temic sclerosis treated with five therapies: mycophenolate mofetil, rituximab, abatacept, nilotinib,

243 Monitored drugs were mycophenolate mofetil, sirolimus, or azathioprine.

244 were treated for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combination of thes

245 ession with oral tacrolimus, prednisone, and mycophenolate mofetil, which has continued until the pre

246 deceased donor KTRs maintained on tacrolimus/mycophenolate mofetil-based regimen along with steroid.

247 sitivity, hepatitis C virus reinfection, and mycophenolate mofetil-free regimens were significant ris

248 s under antithymocyte globulin induction and mycophenolate mofetil-tacrolimus maintenance immunosuppr

249 l islet grafts under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol.

250 ften in patients given cyclophosphamide than mycophenolate mofetil.

251 FK506 but can be blocked by the presence of mycophenolate mofetil.

252 rrow infusion then steroids, tacrolimus, and mycophenolate mofetil.

253 e immunosuppression (IS) with tacrolimus and mycophenolate mofetil.

254 ts were randomized to methotrexate and 39 to mycophenolate mofetil.

255 n between patients receiving methotrexate or mycophenolate mofetil.

256 eiving calcineurin inhibitors, steroids, and mycophenolate mofetil.

257 erious effects of rapamycin, tacrolimus, and mycophenolate mofetil.

258 estimated GFR, male sex, and treatment with mycophenolate mofetil.

259 imen consisting of tacrolimus, steroids, and mycophenolate mofetil.

260 d post-HCT cyclophosphamide, tacrolimus, and mycophenolate mofetil.

261 B cells that persisted after treatment with mycophenolate mofetil.

262 the metabolism of the immunosuppressant drug mycophenolate mofetil.

263 d thymoglobulin, tacrolimus, prednisone, and mycophenolate mofetil.

264 ence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.

265 d were discharged on a calcineurin inhibitor/mycophenolate mofetil/steroid-free immunosuppression.

266 cipients maintained on calcineurin inhibitor/mycophenolate mofetil/steroid-free regimen.

267 oglobulin/interleukin 2 receptor blocker and mycophenolate mofetil/tacrolimus (Tac)/prednisone was em

268 ts were randomized to methotrexate and 16 to mycophenolate mofetil; 30 had acute VKH.

269 The no-ATG group received mycophenolate mofetile + cyclosporin A as graft-versus-h

270 tioning to PBSC h-HSCT with cyclosporine and mycophenolate mofetyl + PTCY (n = 32) or PTCY + ATG (n =

271 Recommendations are impossible for mycophenolate, montelukast, intravenous immunoglobulins,

272 galovirus [CMV]) in KTR on sirolimus (SRL) + mycophenolate (MPA) or SRL + tacrolimus (Tac), relative

273 hs posttransplant among everolimus (EVR) and mycophenolate (MPA) treatment arms and used a time-depen

274 cubated with serial dilutions of tacrolimus, mycophenolate (MPA), sirolimus, tofacitinib, and belatac

275 ves (octyl mycophenolate, MPA-C8E; octadecyl mycophenolate, MPA-C18E; and octadecyl mycophenolamide,

276 Alkyl chain derivatives (octyl mycophenolate, MPA-C8E; octadecyl mycophenolate, MPA-C18

277 ddition of antiproliferative agents (such as mycophenolate or azathioprine) in preventing deteriorati

278 onor transplant recipients received CNI with mycophenolate or methotrexate for GVHD prophylaxis; 1245

279 losporine or tacrolimus plus methotrexate or mycophenolate) or standard GVHD prophylaxis alone.

280 transplant-related drugs such as tacrolimus, mycophenolate, or antithymocyte globulin go on shortage.

281 e regimens including tacrolimus (P=0.001) or mycophenolate (P=0.0025).

282 eiving reduced TAC exposure, prednisone, and mycophenolate, randomized at 3 months to be converted or

283 Mycophenolate reduced the relapse rate by up to 87.4%, w

284 Pediatrics, nontacrolimus/mycophenolate regimens, and nonrenal transplants were ex

285 yclosporin, tacrolimus (Tac), enteric-coated mycophenolate sodium (EC-MPS) and sirolimus (SRL) in ora

286 tudy, the IEM was combined to enteric-coated mycophenolate sodium (ECMPS).

287 with prednisolone, cyclosporine A (CsA), and mycophenolate sodium (MPS) for the first 6 months after

288 AE in patients receiving everolimus (EVR) or mycophenolate sodium (MPS).

289 was significantly higher with enteric-coated mycophenolate sodium versus mycophenolate mofetil at mon

290 itor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacrolimus (TAC), MMF+cyclosporine

291 substance in both mycophenolate mofetil and mycophenolate sodium, and it is widely used after organ

292 included induction therapy with rabbit ATG, mycophenolate sodium, or mycophenolate mofetil and rapid

293 a need for consensus on practical aspects of mycophenolate target concentration intervention in conte

294 ntrol mice, but not Ret(9/-) mice (which had mycophenolate toxicity).

295 Mycophenolate treatment also reduced ENS precursor migra

296 In mice, mycophenolate treatment selectively impaired ENS precurs

297 raft loss at 5 years, whereas tacrolimus and mycophenolate use was associated with reduced risk (RR,

298 The average dose (+/-SD) of mycophenolate was 1.42 +/- 0.3 g/day and the individual

299 ate analysis showed that only the absence of mycophenolate was associated with a better vaccine respo

300 unosuppression, consisting of tacrolimus and mycophenolate, was weaned over 1 year.